Document:

EX-4.7

 Exhibit 4.7 

THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS IN ACCORDANCE WITH
APPLICABLE REGISTRATION REQUIREMENTS OR AN EXEMPTION THEREFROM. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE ISSUER THAT SUCH OFFER, SALE, TRANSFER, PLEDGE OR HYPOTHECATION OTHERWISE COMPLIES WITH
THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS. THIS WARRANT MUST BE SURRENDERED TO THE COMPANY OR ITS TRANSFER AGENT AS A CONDITION PRECEDENT TO THE SALE, TRANSFER, PLEDGE OR HYPOTHECATION OF ANY INTEREST IN ANY OF THE SECURITIES REPRESENTED
HEREBY, EXCEPT AS PROVIDED HEREIN. 
 WARRANT TO PURCHASE SHARES OF COMMON STOCK 

of 
 CONTRAFECT
CORPORATION 
 Dated as of                  

Void after the date specified in Section 8 

No.
 THIS CERTIFIES THAT, for value
received,         , or its registered assigns (the “Holder”), is entitled, subject to the provisions and upon the terms and conditions set forth herein, to purchase from ContraFect
Corporation, a Delaware corporation (the “Company”), Shares (as defined below), in the amounts, at such times and at the price per share set forth in Section 1. The term “Warrant” as used herein
shall include this Warrant and any warrants delivered in substitution or exchange therefor as provided herein. 
 The following is a
statement of the rights of the Holder and the conditions to which this Warrant is subject, and to which Holder, by acceptance of this Warrant, agrees: 

1. Number and Price of Shares; Exercise Period. 

(a) Definition of Shares. “Shares” shall mean shares of the Company’s common stock, par value
$0.0001 per share. 
 (b) Number of Shares. Subject to any previous exercise of the Warrant, the Holder shall have the right to
purchase              Shares. 
 (c) Exercise Price. The exercise
price per Share shall be equal to              (the “Exercise Price”). The Exercise Price shall be subject to adjustment for any future stock splits or reverse stock
splits by the Company. 
 (d) Exercise Period. This Warrant shall be exercisable, in whole or in part, prior to (or in
connection with) the expiration of this Warrant as set forth in Section 8. 

  
 - 1 - 

 2. Exercise of the Warrant. 

(a) Exercise. The purchase rights represented by this Warrant may be exercised at the election of the Holder, in whole or in
part, in accordance with Section 1, by: 
 (i) the tender to the Company at its principal office (or such other office or agency as the
Company may designate) of a notice of exercise in the form of Exhibit A (the “Notice of Exercise”), duly completed and executed by or on behalf of the Holder, together with the surrender of this Warrant; and 

(ii) the payment to the Company of an amount equal to (x) the Exercise Price multiplied by (y) the number of Shares being purchased,
by wire transfer or certified, cashier’s or other check acceptable to the Company and payable to the order of the Company. 
 (b)
Stock Certificates. The rights under this Warrant shall be deemed to have been exercised and the Shares issuable upon such exercise shall be deemed to have been issued immediately prior to the close of business on the date this Warrant
is exercised in accordance with its terms, and the person entitled to receive the Shares issuable upon such exercise shall be treated for all purposes as the holder of record of such Shares as of the close of business on such date. As promptly as
reasonably practicable on or after such date, the Company shall issue and deliver to the person or persons entitled to receive the same a certificate or certificates for that number of shares issuable upon such exercise. In the event that the rights
under this Warrant are exercised in part and have not expired, the Company shall execute and deliver a new Warrant reflecting the number of Shares that remain subject to this Warrant. 

(c) No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of the rights under this Warrant. In lieu of such fractional share to which the Holder would otherwise be entitled, the Company shall make a cash payment equal to the Exercise Price multiplied by such fraction. 

(d) Conditional Exercise. The Holder may exercise this Warrant conditioned upon (and effective immediately prior to) consummation
of any transaction that would cause the expiration of this Warrant pursuant to Section 8 by so indicating in the notice of exercise. 

(e) Reservation of Stock. The Company agrees during the term the rights under this Warrant are exercisable to take all reasonable
action to reserve and keep available from its authorized and unissued Shares (or any such other class or series of stock then issuable upon exercise of this Warrant) for the purpose of effecting the exercise of this Warrant such number of Shares
(and any shares of stock to be issued on conversion of such Shares) as shall from time to time be sufficient to effect the exercise of the rights under this Warrant; and if at any time the number of authorized but unissued Shares (or any such other
class or series of stock then issuable upon exercise of this Warrant) (and any shares of stock to be issued on conversion of such Shares) shall not be sufficient for purposes of the exercise of this Warrant in accordance with its terms and the
conversion of the Shares, without limitation of such other remedies as may be available to the Holder, the Company will use all reasonable efforts to take such corporate action as may be necessary to increase its authorized and unissued Shares (and
any shares of stock to be issued on conversion of such Shares) to a number of Shares as shall be sufficient for such purposes. 
 3.
Replacement of the Warrant. Subject to the receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity
agreement reasonably satisfactory in form and substance to the Company or, in the case of mutilation, on surrender and cancellation of this Warrant, the Company at the expense of the Holder shall execute and deliver, in lieu of this Warrant, a new
warrant of like tenor and amount. 

 4. Transfer of the Warrant. 

(a) Warrant Register. The Company shall maintain a register (the “Warrant Register”) containing the name
and address of the Holder. Until this Warrant is transferred on the Warrant Register in accordance herewith, the Company may treat the Holder as shown on the Warrant Register as the absolute owner of this Warrant for all purposes, notwithstanding
any notice to the contrary. Any Holder of this Warrant (or of any portion of this Warrant) may change its address as shown on the Warrant Register by written notice to the Company requesting a change. 

(b) Warrant Agent. The Company may appoint an agent for the purpose of maintaining the Warrant Register referred to in
Section 4(a), issuing the Shares or other securities then issuable upon the exercise of the rights under this Warrant, exchanging this Warrant, replacing this Warrant or conducting related activities. 

(c) Transferability of the Warrant. Subject to the provisions of this Warrant with respect to compliance with the Securities Act
and limitations on assignments and transfers, including without limitation compliance with the restrictions on transfer set forth in Section 5, title to this Warrant may be transferred by endorsement (by the transferor and the transferee
executing the assignment form attached as Exhibit B (the “Assignment Form”)) and delivery in the same manner as a negotiable instrument transferable by endorsement and delivery. 

(d) Exchange of the Warrant upon a Transfer. On surrender of this Warrant (and a properly endorsed Assignment Form) for exchange,
subject to the provisions of this Warrant with respect to compliance with the Securities Act and limitations on assignments and transfers, the Company shall issue to or on the order of the Holder a new warrant or warrants of like tenor, in the name
of the Holder or as the Holder (on payment by the Holder of any applicable transfer taxes) may direct, for the number of shares issuable upon exercise hereof, and the Company shall register any such transfer upon the Warrant Register. This Warrant
(and the securities issuable upon exercise of the rights under this Warrant) must be surrendered to the Company or its warrant or transfer agent, as applicable, as a condition precedent to the sale, pledge, hypothecation or other transfer of any
interest in any of the securities represented hereby, except as provided in Section 5(b). 
 (e) Taxes. In no event shall
the Company be required to pay any tax which may be payable in respect of any transfer involved in the issue and delivery of any certificate in a name other than that of the Holder, and the Company shall not be required to issue or deliver any such
certificate unless and until the person or persons requesting the issue thereof shall have paid to the Company the amount of such tax or shall have established to the satisfaction of the Company that such tax has been paid or is not payable. 

5. Restrictions on Transfer of the Warrant and Shares; Compliance with Securities Laws. By acceptance of this Warrant, the Holder agrees
to comply with the following: 
 (a) Restrictions on Transfers. Except as provided in Section 5(b), this Warrant may not
be transferred or assigned in whole or in part without the Company’s prior written consent (which shall not be unreasonably withheld), and any attempt by Holder to transfer or assign any rights, duties or obligations that arise under this
Warrant without such permission shall be void. Any transfer of this Warrant or the Shares or the shares of common stock issuable upon conversion of the Shares (the “Securities”) must be in compliance with all applicable
federal and state securities laws. The Holder agrees not to make any sale, assignment, transfer, pledge or other disposition of all or any portion of the Securities, or any beneficial interest therein, unless and until the transferee thereof has
agreed in writing for the benefit of the Company to take and hold such Securities subject to, and to be bound by, the terms and conditions set forth in this Warrant to the same extent as if the transferee were the original Holder hereunder, and 

 (i) there is then in effect a registration statement under the Securities Act covering such
proposed disposition and such disposition is made in accordance with such registration statement, or 
 (ii) (A) such Holder shall have
given prior written notice to the Company of such Holder’s intention to make such disposition and shall have furnished the Company with a detailed description of the manner and circumstances of the proposed disposition, (B) the transferee
shall have confirmed to the satisfaction of the Company in writing, substantially in the form of Exhibit A-1, that the Securities are being acquired (i) solely for the transferee’s own account and not as a nominee for any other party,
(ii) for investment and (iii) not with a view toward distribution or resale, and shall have confirmed such other matters related thereto as may be reasonably requested by the Company, including that the transferee is in compliance with all
applicable laws and (C) such Holder shall have furnished the Company with (i) an opinion of counsel, reasonably satisfactory to the Company, to the effect that such disposition will not require registration of such Securities under the
Securities Act or (ii) a “no action” letter from the Securities and Exchange Commission to the effect that the transfer of such Securities without registration will not result in a recommendation by the staff of the Securities and
Exchange Commission that action be taken with respect thereto, whereupon such Holder shall be entitled to transfer such Securities in accordance with the terms of the notice delivered by the Holder to the Company. 

(b) Permitted Transfers. Permitted transfers include (i) a transfer not involving a change in beneficial ownership,
(ii) transactions involving the distribution without consideration of Securities by any Holder to (x) a parent, subsidiary or other affiliate of a Holder that is a corporation, (y) any of the Holder’s partners, members or other
equity owners, or retired partners or members, or to the estate of any of its partners, members or other equity owners or retired partners or members, or (z) a venture capital fund that is controlled by or under common control with one or more
general partners or managing members of, or shares the same management company with, the Holder or (iii) transfers to “accredited investors” within the meaning of Regulation D under the Securities Act; provided, in each of
(i)-(iii) above, that the Holder shall give written notice to the Company of the Holder’s intention to effect such disposition and shall have furnished the Company with a detailed description of the manner and circumstances of the proposed
disposition at least five (5) business days prior to the intended transfer, and, in (iii) above, that (A) the transferee shall have confirmed to the Company in writing, substantially in the form of Exhibit A-1, that the Securities are
being acquired (1) solely for the transferee’s own account and not as a nominee for any other party, (2) for investment and (3) not with a view toward distribution or resale, and shall have confirmed such other matters related
thereto as may be reasonably requested by the Company, including that the transferee is in compliance with all applicable laws and (B) such Holder shall have furnished the Company with (1) an opinion of counsel, reasonably satisfactory to
the Company, to the effect that such disposition will not require registration of such Securities under the Securities Act or (2) a “no action” letter from the Securities and Exchange Commission to the effect that the transfer of such
Securities without registration will not result in a recommendation by the staff of the Securities and Exchange Commission that action be taken with respect thereto, whereupon such Holder shall be entitled to transfer such Securities in accordance
with the terms of the notice delivered by the Holder to the Company. 
 (c) Investment Representation Statement. Unless the
rights under this Warrant are exercised pursuant to an effective registration statement under the Securities Act that includes the Shares with respect to which the Warrant was exercised, it shall be a condition to any exercise of the rights under
this Warrant that the Holder shall have confirmed to the satisfaction of the Company in writing, substantially in the form of Exhibit A-1, that the Shares so purchased are being acquired solely for the Holder’s own account and not as a
nominee for any other party, for investment and not with a view toward distribution or resale and that the Holder shall have confirmed such other matters related thereto as may be reasonably requested by the Company. 

 (d) Securities Law Legend. The Securities shall (unless otherwise permitted by the
provisions of this Warrant) be stamped or imprinted with a legend substantially similar to the following (in addition to any legend required by state securities laws): 

THE SECURITIES REPRESENTED BY THIS CERTIFICATE AND THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE NOT BEEN REGISTERED UNDER
THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATES. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR RESOLD EXCEPT
AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR AN EXEMPTION THEREFROM. HOLDERS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME.
THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY TO THE EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT AND APPLICABLE STATE SECURITIES LAWS. NOTWITHSTANDING
THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES. ANY TRANSFEREE OF THIS NOTE SHOULD CAREFULLY REVIEW THE TERMS OF THIS NOTE. THE PRINCIPAL
AMOUNT REPRESENTED BY THIS NOTE AND THE SECURITIES ISSUABLE UPON CONVERSION HEREOF MAY BE LESS THAN THE AMOUNT SET FORTH ON THE FACE HEREOF PURSUANT TO SECTION 2(d) OF THIS NOTE. 

(e) Market Stand-off Legend. The Shares and common stock issued upon exercise hereof or conversion thereof shall also be stamped
or imprinted with a legend in substantially the following form: 
 THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO RESTRICTIONS ON
TRANSFERABILITY AND RESALE, INCLUDING A LOCK-UP PERIOD IN THE EVENT OF A PUBLIC OFFERING, AS SET FORTH IN THE WARRANT PURSUANT TO WHICH THESE SHARES WERE ISSUED, A COPY OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE COMPANY. 

(f) Instructions Regarding Transfer Restrictions. The Holder consents to the Company making a notation on its records and giving
instructions to any transfer agent in order to implement the restrictions on transfer established in this Section 5. 
 (g)
Removal of Legend. The legend referring to federal and state securities laws identified in Section 5(d) stamped on a certificate evidencing the Shares (and the common stock issuable upon conversion thereof) and the stock transfer
instructions and record notations with respect to such securities shall be removed and the Company shall issue a certificate without such legend to the holder of such securities if (i) such securities are registered under the Securities Act, or
(ii) such holder provides the Company with an opinion of counsel reasonably acceptable to the Company to the effect that a sale or transfer of such securities may be made without registration or qualification. 

 6. Adjustments. Subject to the expiration of this Warrant pursuant to Section 8, the
number and kind of shares purchasable hereunder and the Exercise Price therefor are subject to adjustment from time to time, as follows: 

(a) Merger or Reorganization. If at any time there shall be a Fundamental Transaction (as defined in Section 7(a) of the
Notes) involving the Company (other than as otherwise provided for herein or as would cause the expiration of this Warrant under Section 8) in which shares of the Company’s stock are converted into or exchanged for securities, cash or
other property, then, as a part of such Fundamental Transaction, lawful provision shall be made so that the Holder shall thereafter be entitled to receive upon exercise of this Warrant, the kind and amount of securities, cash or other property of
the successor corporation resulting from such Fundamental Transaction, equivalent in value to that which a holder of the Shares deliverable upon exercise of this Warrant would have been entitled in such Fundamental Transaction if the right to
purchase the Shares hereunder had been exercised immediately prior to such Fundamental Transaction. In any such case, appropriate adjustment (as determined in good faith by the Board of Directors of the successor corporation) shall be made in the
application of the provisions of this Warrant with respect to the rights and interests of the Holder after such Fundamental Transaction to the end that the provisions of this Warrant shall be applicable after the event, as near as reasonably may be,
in relation to any shares or other securities deliverable after that event upon the exercise of this Warrant. 
 (b) Reclassification
of Shares. If the securities issuable upon exercise of this Warrant are changed into the same or a different number of securities of any other class or classes by reclassification, capital reorganization, conversion of all outstanding shares
of the relevant class or series (other than as would cause the expiration of this Warrant pursuant to Section 8) or otherwise (other than as otherwise provided for herein) (a “Reclassification”), then, in any such event,
in lieu of the number of Shares which the Holder would otherwise have been entitled to receive, the Holder shall have the right thereafter to exercise this Warrant for a number of shares of such other class or classes of stock that a holder of the
number of securities deliverable upon exercise of this Warrant immediately before that change would have been entitled to receive in such Reclassification, all subject to further adjustment as provided herein with respect to such other shares. 

(c) Subdivisions and Combinations. In the event that the outstanding shares of the securities issuable upon exercise of this
Warrant are subdivided (by stock split, by payment of a stock dividend or otherwise) into a greater number of shares of such securities, the number of Shares issuable upon exercise of the rights under this Warrant immediately prior to such
subdivision shall, concurrently with the effectiveness of such subdivision, be proportionately increased, and the Exercise Price shall be proportionately decreased, and in the event that the outstanding shares of the securities issuable upon
exercise of this Warrant are combined (by reclassification or otherwise) into a lesser number of shares of such securities, the number of Shares issuable upon exercise of the rights under this Warrant immediately prior to such combination shall,
concurrently with the effectiveness of such combination, be proportionately decreased, and the Exercise Price shall be proportionately increased. 

(d) Redemption. In the event that all of the outstanding shares of the securities issuable upon exercise of this Warrant are
redeemed in accordance with the Company’s certificate of incorporation, this Warrant shall thereafter be exercisable for a number of shares of the Company’s common stock equal to the number of shares of common stock that would have been
received if this Warrant had been exercised in full immediately prior to such redemption and any securities received thereupon had been simultaneously converted into common stock. 

(e) Notice of Adjustments. Upon any adjustment in accordance with this Section 6, the Company shall give notice thereof to
the Holder, which notice shall state the event giving rise to the adjustment, the Exercise Price as adjusted and the number of securities or other property purchasable upon the exercise of the rights under this Warrant, setting forth in reasonable
detail the method of calculation of each. 

 The Company shall, upon the written request of any Holder, furnish or cause to be furnished to such Holder a
certificate setting forth (i) such adjustments, (ii) the Exercise Price at the time in effect and (iii) the number of securities and the amount, if any, of other property that at the time would be received upon exercise of this
Warrant. 
 7. Notification of Certain Events. Prior to the expiration of this Warrant pursuant to Section 8, in the event that
the Company shall authorize: 
 (a) the issuance of any dividend or other distribution on the capital stock of the Company (other than
(i) dividends or distributions otherwise provided for in Section 6, (ii) repurchases of common stock issued to or held by employees, officers, directors or consultants of the Company or its subsidiaries upon termination of their
employment or services pursuant to agreements providing for the right of said repurchase; or (iii) repurchases of common stock issued to or held by employees, officers, directors or consultants of the Company or its subsidiaries pursuant to
rights of first refusal or first offer contained in agreements providing for such rights), whether in cash, property, stock or other securities; 

(b) the voluntary liquidation, dissolution or winding up of the Company; or 

(c) any transaction resulting in the expiration of this Warrant pursuant to Section 8(b) 

the Company shall send to the Holder of this Warrant at least 10 business days prior written notice of the date on which a record shall be taken for any such
dividend or distribution specified in clause (a) or the expected effective date of any such other event specified in clause (b) or (c), as applicable. The notice provisions set forth in this section may be shortened or waived prospectively
or retrospectively by the consent of the holders of a majority of the Shares issuable upon exercise of the rights under the Warrants. 
 8.
Expiration of the Warrant. This Warrant shall expire and shall no longer be exercisable as of the earlier of: 
 (a) 5:00 p.m.,
Eastern time, on             , 20    ; 
 (b) (i) the
acquisition of the Company by another entity by means of any transaction or series of related transactions to which the Company is a party (including, without limitation, any stock acquisition, reorganization, merger or consolidation, but excluding
any sale of stock for capital raising purposes and any transaction effected primarily for purposes of changing the Company’s jurisdiction of incorporation) other than a transaction or series of related transactions in which the holders of the
voting securities of the Company outstanding immediately prior to such transaction or series of related transactions retain, immediately after such transaction or series of transactions, as a result of shares in the Company held by such holders
prior to such transaction or series of transactions, at least a majority of the total voting power represented by the outstanding voting securities of the Company or such other surviving or resulting entity (or if the Company or such other surviving
or resulting entity is a wholly-owned subsidiary immediately following such acquisition, its parent), or (ii) a sale, lease or other disposition of all or substantially all of the assets of the Company and its subsidiaries taken as a whole by
means of any transaction or series of related transactions, except where such sale, lease or other disposition is to a wholly-owned subsidiary of the Company; 

9. No Rights as a Stockholder. Nothing contained herein shall entitle the Holder to any rights as a stockholder of the Company or to be
deemed the holder of any securities that may at any time be issuable on the exercise of the rights hereunder for any purpose nor shall anything contained herein be construed to confer upon the Holder, as such, any right to vote for the election of
directors or upon any matter submitted to stockholders at any meeting thereof, or to give or withhold consent to any corporate action (whether upon any 

 
recapitalization, issuance of stock, reclassification of stock, change of par value or change of stock to no par value, consolidation, merger, conveyance or otherwise) or to receive notice of
meetings, or to receive dividends or subscription rights or any other rights of a stockholder of the Company until the rights under the Warrant shall have been exercised and the Shares purchasable upon exercise of the rights hereunder shall have
become deliverable as provided herein. 
 10. Market Stand-off. 

(a) Agreement to Lock-Up in connection with IPO. The Holder of this Warrant hereby agrees that such Holder shall not sell or
otherwise transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale, of any common stock (or other securities) of the Company held by the Holder
(other than those included in the registration) during the one hundred and eighty (180) day period following the effective date of the registration statement for the IPO filed under the Securities Act (or such other period as may be requested
by the Company or an underwriter to accommodate regulatory restrictions on (i) the publication or other distribution of research reports and (ii) analyst recommendations and opinions, including, but not limited to, the restrictions
contained in FINRA NASD Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto) (the “Trading Date”). The obligations described in this section shall not apply to a registration
relating solely to employee benefit plans on Form S-l or Form S-8 or similar forms that may be promulgated in the future, or a registration relating solely to a transaction on Form S-4 or similar forms that may be promulgated in the future. The
Company may impose stop-transfer instructions and may stamp each certificate with a legend as substantially set forth in Section 5(e) with respect to the shares of common stock (or other securities) subject to the foregoing restriction until
the end of such one hundred and eighty (180) day (or other) period. The restrictions set forth in this Section 10 shall be applicable to the Holder only if all officers and directors are subject to the same restrictions and the Company
uses commercially reasonable efforts to obtain a similar agreement from all stockholders individually owning more than two percent (2%) of the Company’s outstanding common stock (after giving effect to conversion into common stock of all
outstanding preferred stock). The Holder agrees to execute a market stand-off agreement with the underwriters in the offering in customary form consistent with the provisions of this section. Any discretionary waiver or termination by the Company or
the underwriters of the restrictions of any or all of such agreements with an officer or director of the Company or a stockholder individually holding greater than one percent (1%) of the Company’s outstanding capital stock, calculated on
a fully-diluted basis, shall apply pro rata to all holders subject to such agreements, based on the number of shares subject to such agreements. 

(b) Agreement to Lock-Up in connection with Form 10 Registration Statement. Upon the Company’s filing of a Form 10
registration statement, Holder hereby agrees that Holder will not, without the prior written consent of the Company, during the period commencing on the date on which the Securities and Exchange Commission informs the Company that it has completed
its review of the Form 10 registration statement and ending 180 days following the Trading Date, (a) lend, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant
any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of common stock or (b) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the
economic consequences of ownership of the common stock, whether any such transaction described in clause (a) or (b) above is to be settled by delivery of common stock or other securities, in cash or otherwise. The foregoing
provisions shall not apply to (i) shares of common stock acquired in open market transactions after the Trading Date; (ii) transactions relating to shares of common stock purchased in accordance with clause (i); (iii) in the case of a
Holder that is an entity, a transfer by such Holder to its stockholders, members, partners or other equity holders, provided that no consideration is actually paid for such transfer; (iv) a repurchase of common stock by the Company at a price
no greater than that originally paid by such Holder for such common stock and pursuant to an agreement containing vesting and/or repurchase provisions approved by a majority of the Company’s board of directors (the “Board of
Directors”); (v) in the case of a Holder that is a 

 
natural person, a transfer of common stock made for bona fide estate planning purposes, either during such Holder’s lifetime or on death by will or intestacy to his or her family members or
any other person approved by the Board of Directors, or any custodian or trustee of any trust, partnership or limited liability company for the benefit of, or the ownership interests of which are owned wholly by, such Holder or any such family
members, provided in all cases referred to in this clause (v) that no consideration is actually paid for such transfer and (vi) the receipt of a stock option, shares of restricted common stock or other awards, or the exercise of a stock
option, granted under the Company’s 2008 Equity Incentive Plan, as amended, or other stock option plan approved by a majority of the Board of Directors. The Holder further agrees to execute such agreements as may be reasonably requested by
the Company that are consistent with the provisions of this section or that are necessary to give further effect thereto. 
 11. Demand
Registration. The Company covenants and agrees as follows: 
 (a) If at any time before the expiration of this Warrant and after one
hundred eighty (180) days after the effective date of the registration statement for the Company’s IPO, the Holder may request that the Company file a Form S-1 or S-3 registration statement, as applicable, with respect to any Securities
outstanding, in which case the Company shall, as soon as practicable, and in any event within ninety (90) days after the date such request is given by such Holder, file such Form S-1 or S-3 registration statement under the Securities Act
covering all securities to be registered pursuant to the request of such Holder and any other securities to be included in the Company’s reasonable discretion, subject to the limitations of Section 11(b). Upon the Company’s receipt of
a demand for registration with respect to any outstanding warrants issued in connection with the issuance of the Company’s 8% Convertible Notes due 2015 (collectively, the “Notes Warrants”), the Company may, at its
option, send a written notice (a “Registration Notice”) to all holders of Notes Warrants (including the Holder) that the Company intends to file a registration statement on Form S-1 or S-3 (such registration statement, the
“Notes Warrant Registration Statement”) for all of the Shares underlying the Notes Warrants. Such Registration Notice shall be sent to all such holders no less than 30 days prior to the effectiveness of the Form S-1 or S-3
Registration Statement and shall inform such holders of their right to include their Shares in the registration statement. Any holder exercising such right shall promptly provide the Company with the information requested in the Registration Notice.
If the Holder elects not to request that the Company include its Securities in the Notes Warrant Registration Statement, or fails to provide reasonably requested information to the Company required for such registration in a timely manner, the
Holder’s rights under this Section 11(a) shall terminate. 
 (b) Notwithstanding the foregoing obligations, if the Company
furnishes to the Holder requesting a registration pursuant to Section 11(a) a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Company’s Board of Directors it would be
materially detrimental to the Company and its stockholders for such registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action
would (i) materially interfere with a significant acquisition, corporate reorganization, or other similar transaction involving the Company; (ii) require premature disclosure of material information that the Company has a bona fide
business purpose for preserving as confidential; or (iii) render the Company unable to comply with requirements under the Securities Act or other applicable laws, then the Company shall have the right to defer taking action with respect to such
filing, and any time periods with respect to filing or effectiveness thereof shall be tolled correspondingly, for a period of not more than one hundred and eighty (180) days after the request of such Holder; provided, however, that the Company
may not invoke this right more than once in any twelve (12) month period. 
 (c) The Company shall not be obligated to effect, or to
take any action to effect, any registration pursuant to Section 11(a) (i) during the period that is ninety (90) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is one hundred
eighty (180) days after the effective date of, a Company-initiated registration, provided that the Company is actively employing in good faith 

 
commercially reasonable efforts to cause such registration statement to become effective; (ii) after the Company has effected one registration pursuant to Section 11(a); or
(iii) if such Holder proposes to dispose of Securities that may be immediately registered on Form S-3. A registration shall not be counted as “effected” for purposes of this Section 11(c) until such time as the applicable
registration statement has been declared effective by the SEC, unless such Holder withdraws its request for such registration, elects not to pay the registration expenses therefor, and forfeits its right to one demand registration statement, in
which case such withdrawn registration statement shall be counted as “effected” for purposes of this Section 11(c). 
 12.
Representations and Warranties of the Holder. By acceptance of this Warrant, the Holder represents and warrants to the Company as follows: 

(a) No Registration. The Holder understands that the Securities have not been, and will not be, registered under the Securities
Act by reason of a specific exemption from the registration provisions of the Securities Act, the availability of which depends upon, among other things, the bona fide nature of the investment intent and the accuracy of the Holder’s
representations as expressed herein or otherwise made pursuant hereto. 
 (b) Investment Intent. The Holder is acquiring the
Securities for investment for its own account, not as a nominee or agent, and not with a view to, or for resale in connection with, any distribution thereof. The Holder has no present intention of selling, granting any participation in, or otherwise
distributing the Securities, nor does it have any contract, undertaking, agreement or arrangement for the same. 
 (c) Investment
Experience. The Holder has substantial experience in evaluating and investing in private placement transactions of securities in companies similar to the Company, and has such knowledge and experience in financial or business matters so that
it is capable of evaluating the merits and risks of its investment in the Company and protecting its own interests. 
 (d) Speculative
Nature of Investment. The Holder understands and acknowledges that the Company has a limited financial and operating history and that its investment in the Company is highly speculative and involves substantial risks. The Holder can bear the
economic risk of its investment and is able, without impairing its financial condition, to hold the Securities for an indefinite period of time and to suffer a complete loss of its investment. 

(e) Access to Data. The Holder has had an opportunity to ask questions of officers of the Company, which questions were answered
to its satisfaction. The Holder believes that it has received all the information that it considers necessary or appropriate for deciding whether to acquire the Securities. The Holder understands that any such discussions, as well as any information
issued by the Company, were intended to describe certain aspects of the Company’s business and prospects, but were not necessarily a thorough or exhaustive description. The Holder acknowledges that any business plans prepared by the Company
have been, and continue to be, subject to change and that any projections included in such business plans or otherwise are necessarily speculative in nature, and it can be expected that some or all of the assumptions underlying the projections will
not materialize or will vary significantly from actual results. 
 (f) Accredited Investor. The Holder represents that it is an
“accredited investor” within the meaning of Regulation D under the Securities Act and agrees to submit to the Company further assurances of such status as may be reasonably requested by the Company. 

(g) Residency. The residency of Holder (or, in the case of a partnership or corporation, such entity’s principal place of
business) is correctly set forth on the signature page hereto. 

 (h) Restrictions on Resales. The Holder acknowledges that the Securities must be
held indefinitely unless subsequently registered under the Securities Act or an exemption from such registration is available. The Holder is aware of the provisions of Rule 144 promulgated under the Securities Act, which permit resale of shares
purchased in a private placement subject to the satisfaction of certain conditions, which may include, among other things, the availability of certain current public information about the Company; the resale occurring not less than a specified
period after a party has purchased and paid for the security to be sold; the number of shares being sold during any three-month period not exceeding specified limitations; the sale being effected through a “broker’s transaction,” a
transaction directly with a “market maker” or a “riskless principal transaction” (as those terms are defined in the Securities Act or the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated
thereunder); and the filing of a Form 144 notice, if applicable. The Holder acknowledges and understands that the Company may not be satisfying the current public information requirement of Rule 144 at the time the Holder wishes to sell the
Securities and that, in such event, the Holder may be precluded from selling the Securities under Rule 144 even if the other applicable requirements of Rule 144 have been satisfied. The Holder acknowledges that, in the event the applicable
requirements of Rule 144 are not met, registration under the Securities Act or an exemption from registration will be required for any disposition of the Securities. The Holder understands that, although Rule 144 is not exclusive, the
Securities and Exchange Commission has expressed its opinion that persons proposing to sell restricted securities received in a private offering other than in a registered offering or pursuant to Rule 144 will have a substantial burden of proof
in establishing that an exemption from registration is available for such offers or sales and that such persons and the brokers who participate in the transactions do so at their own risk. 

(i) No Public Market. The Holder understands and acknowledges that no public market now exists for any of the securities issued
by the Company and that the Company has made no assurances that a public market will ever exist for the Company’s securities. 
 (j)
Brokers and Finders. The Holder has not engaged any brokers, finders or agents in connection with the Securities, and the Company has not incurred nor will incur, directly or indirectly, as a result of any action taken by the Holder,
any liability for brokerage or finders’ fees or agents’ commissions or any similar charges in connection with the Securities. 

(k) Legal Counsel. The Holder has had the opportunity to review this Warrant, the exhibits and schedules attached hereto and the
transactions contemplated by this Warrant with its own legal counsel. The Holder is not relying on any statements or representations of the Company or its agents for legal advice with respect to this investment or the transactions contemplated by
this Warrant. 
 (l) Tax Advisors. The Holder has reviewed with its own tax advisors the U.S. federal, state and local and
non-U.S. tax consequences of this investment and the transactions contemplated by this Warrant. With respect to such matters, the Holder relies solely on any such advisors and not on any statements or representations of the Company or any of its
agents, written or oral. The Holder understands that it (and not the Company) shall be responsible for its own tax liability that may arise as a result of this investment and the transactions contemplated by this Warrant. 

13. Miscellaneous. 
 (a)
Amendments. Except as expressly provided herein, neither this Warrant nor any term hereof may be amended, waived, discharged or terminated other than by a written instrument referencing this Warrant and signed by the Company and the
Holder. 
 (b) Waivers. No waiver of any single breach or default shall be deemed a waiver of any other breach or default
theretofore or thereafter occurring. 

 (c) Notices. All notices and other communications required or permitted hereunder
shall be in writing and shall be mailed by registered or certified mail, postage prepaid, sent by facsimile or electronic mail (if to the Holder) or otherwise delivered by hand, messenger or courier service addressed: 

(i) if to the Holder, to the Holder at the Holder’s address, facsimile number or electronic mail address as shown in the Company’s
records, as may be updated in accordance with the provisions hereof, or until any such Holder so furnishes an address, facsimile number or electronic mail address to the Company, then to and at the address, facsimile number or electronic mail
address of the last holder of this Warrant for which the Company has contact information in its records; or 
 (ii) if to the Company, to
the attention of the Chief Executive Officer or Chief Financial Officer of the Company at the Company’s address as shown on the signature page hereto, or at such other current address as the Company shall have furnished to the Holder. 

Each such notice or other communication shall for all purposes of this Warrant be treated as effective or having been given (i) if
delivered by hand, messenger or courier service, when delivered (or if sent via a nationally-recognized overnight courier service, freight prepaid, specifying next-business-day delivery, one business day after deposit with the courier), or
(ii) if sent by mail, at the earlier of its receipt or five days after the same has been deposited in a regularly maintained receptacle for the deposit of the United States mail, addressed and mailed as aforesaid, or (iii) if sent via
facsimile, upon confirmation of facsimile transfer or, if sent via electronic mail, upon confirmation of delivery when directed to the relevant electronic mail address, if sent during normal business hours of the recipient, or if not sent during
normal business hours of the recipient, then on the recipient’s next business day. In the event of any conflict between the Company’s books and records and this Warrant or any notice delivered hereunder, the Company’s books and
records will control absent fraud or error. 
 (d) Governing Law. This Warrant and all actions arising out of or in connection
with this Warrant shall be governed by and construed in accordance with the laws of the State of Delaware, without regard to the conflicts of law provisions of the State of Delaware, or of any other state. 

(e) Jurisdiction and Venue. Each of the Holder and the Company irrevocably consents to the exclusive jurisdiction of, and venue
in, the state courts in the State of Delaware (or in the event of exclusive federal jurisdiction, the federal district courts in the State of Delaware), in connection with any matter based upon or arising out of this Warrant or the matters
contemplated herein, and agrees that process may be served upon them in any manner authorized by the laws of the State of Delaware for such persons. 

(f) Titles and Subtitles. The titles and subtitles used in this Warrant are used for convenience only and are not to be
considered in construing or interpreting this Warrant. All references in this Warrant to sections, paragraphs and exhibits shall, unless otherwise provided, refer to sections and paragraphs hereof and exhibits attached hereto. 

(g) Severability. If any provision of this Warrant becomes or is declared by a court of competent jurisdiction to be illegal,
unenforceable or void, portions of such provision, or such provision in its entirety, to the extent necessary, shall be severed from this Warrant, and such illegal, unenforceable or void provision shall be replaced with a valid and enforceable
provision that will achieve, to the extent possible, the same economic, business and other purposes of the illegal, unenforceable or void provision. The balance of this Warrant shall be enforceable in accordance with its terms. 

(h) Waiver of Jury Trial; Judicial Reference. EACH OF THE HOLDER AND THE COMPANY WAIVES, TO THE FULLEST EXTENT PERMITTED BY
LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATED TO THIS WARRANT. This paragraph shall not restrict the Holder or the Company from exercising remedies under
the Uniform Commercial Code or from exercising pre-judgment remedies under applicable law. 

 (i) Saturdays, Sundays and Holidays. If the last or appointed day for the taking of
any action or the expiration of any right required or granted herein shall be a Saturday, Sunday or U.S. federal holiday, then such action may be taken or such right may be exercised on the next succeeding day that is not a Saturday, Sunday or U.S.
federal holiday. 
 (j) Rights and Obligations Survive Exercise of the Warrant. Except as otherwise provided herein, the rights
and obligations of the Company and the Holder under this Warrant shall survive exercise of this Warrant. 
 (k) Entire
Agreement. Except as expressly set forth herein, this Warrant (including the exhibits attached hereto) constitutes the entire agreement and understanding of the Company and the Holder with respect to the subject matter hereof and supersede
all prior agreements and understandings relating to the subject matter hereof. 
 (signature page follows) 

 The Company and the Holder sign this Warrant as of the date stated on the first page. 

 

			
	CONTRAFECT CORPORATION
		
	By:	 	  

	
	Name: Julia P. Gregory
	
	Title: Chief Executive Officer
	
	Address:
	
	28 Wells Avenue, Third Floor
	Yonkers, NY 10701

  

			
	AGREED AND ACKNOWLEDGED,
	
	[                    ]
		
	By:	 	  

		
	Name:	 	  

		
	Title:	 	  

	
	Address:
	
	Fax number:
	
	Email address:

 Signature Page to Warrant 

 EXHIBIT A 

NOTICE OF EXERCISE 
  

	TO:	CONTRAFECT CORPORATION (the “Company”) 

  

	Attention:	Chief Executive Officer / Chief Financial Officer 

  

	(1)	Exercise. The undersigned elects to purchase the following pursuant to the terms of the attached warrant: 

 

					
	Number of shares:	 	  
	  	
			
	Type of security:	 	  
	  	

  

	(2)	Method of Exercise. The undersigned elects to exercise the attached warrant pursuant to: 

  

	 	 ̈	A cash payment, and tenders herewith payment of the purchase price for such shares in full, together with all applicable transfer taxes, if any. 

 

	(3)	Conditional Exercise. Is this a conditional exercise pursuant to Section 2(d): 

  

	 	 ̈	Yes              ̈       No 

If “Yes,” indicate the applicable condition: 

                       
                                         
                                         
                                         
                                         
                                         
           
  

	(4)	Stock Certificate. Please issue a certificate or certificates representing the shares in the name of: 

  

							
	 ̈    	  	The undersigned	  		  	
				
	 ̈	  	Other—Name:	  	  
	  	
				
		  	Address:	  	  
	  	
				
		  		  	  
	  	

  

	(5)	Unexercised Portion of the Warrant. Please issue a new warrant for the unexercised portion of the attached warrant in the name of: 

 

							
	 ̈    	  	The undersigned	  		  	
				
	 ̈	  	Other—Name:	  	  
	  	
				
		  	Address:	  	  
	  	
				
		  		  	  
	  	

  

	 	 ̈	Not applicable 

	(6)	Investment Intent. The undersigned represents and warrants that the aforesaid shares are being acquired for investment for its own account, not as a nominee or agent, and not with a view to, or for resale in
connection with, the distribution thereof, and that the undersigned has no present intention of selling, granting any participation in, or otherwise distributing the shares, nor does it have any contract, undertaking, agreement or arrangement for
the same, and all representations and warranties of the undersigned set forth in Section 12 of the attached warrant are true and correct as of the date hereof. 

 

	(7)	Investment Representation Statement and Market Stand-Off Agreement. The undersigned has executed, and delivers herewith, and is in substantive agreement with all applicable provisions of, an Investment
Representation Statement and Market Stand-Off Agreement in a form substantially similar to the form attached to the warrant as Exhibit A-1. 

  

	(8)	Consent to Receipt of Electronic Notice. Subject to the limitations set forth in Delaware General Corporation Law §232(e), the undersigned consents to the delivery of any notice to stockholders given by the
Company under the Delaware General Corporation Law or the Company’s certificate of incorporation or bylaws by (i) facsimile telecommunication to the facsimile number provided below (or to any other facsimile number for the undersigned in
the Company’s records), (ii) electronic mail to the electronic mail address provided below (or to any other electronic mail address for the undersigned in the Company’s records), (iii) posting on an electronic network together
with separate notice to the undersigned of such specific posting or (iv) any other form of electronic transmission (as defined in the Delaware General Corporation Law) directed to the undersigned. This consent may be revoked by the undersigned
by written notice to the Company and may be deemed revoked in the circumstances specified in Delaware General Corporation Law §232. 

  

	
	  

	(Print name of the warrant holder)
	
	  

	(Signature)
	
	  

	(Name and title of signatory, if applicable)
	
	  

	(Date)
	
	  

	(Fax number)
	
	  

	(Email address)

 EXHIBIT A-l 

INVESTMENT REPRESENTATION STATEMENT 

AND 
 MARKET STAND-OFF
AGREEMENT 
  

			
	INVESTOR:	  	AS IDENTIFIED ON THE SIGNATURE PAGE HERETO
		
	COMPANY:	  	CONTRAFECT CORPORATION
		
	SECURITIES:	  	THE WARRANT ISSUED ON             (THE “WARRANT”) AND THE SECURITIES ISSUED OR ISSUABLE UPON EXERCISE THEREOF (INCLUDING UPON SUBSEQUENT CONVERSION
OF THOSE SECURITIES)
		
	DATE:	  	             
        

 In connection with the purchase or acquisition of the above-listed Securities, the undersigned investor (the
“Investor”) represents and warrants to, and agrees with, the Company as follows: 
 1. No Registration. The Investor
understands that the Securities have not been, and will not be, registered under the Securities Act of 1933, as amended (the “Securities Act”), by reason of a specific exemption from the registration provisions of the
Securities Act, the availability of which depends upon, among other things, the bona fide nature of the investment intent and the accuracy of the Investor’s representations as expressed herein or otherwise made pursuant hereto. 

2. Investment Intent. The Investor is acquiring the Securities for investment for its own account, not as a nominee or agent, and not
with a view to, or for resale in connection with, any distribution thereof. The Investor has no present intention of selling, granting any participation in, or otherwise distributing the Securities, nor does it have any contract, undertaking,
agreement or arrangement for the same. 
 3. Investment Experience. The Investor has substantial experience in evaluating and
investing in private placement transactions of securities in companies similar to the Company, and has such knowledge and experience in financial or business matters so that it is capable of evaluating the merits and risks of its investment in the
Company and protecting its own interests. 
 4. Speculative Nature of Investment. The Investor understands and acknowledges that the
Company has a limited financial and operating history and that its investment in the Company is highly speculative and involves substantial risks. The Investor can bear the economic risk of its investment and is able, without impairing its financial
condition, to hold the Securities for an indefinite period of time and to suffer a complete loss of its investment. 
 5. Access to
Data. The Investor has had an opportunity to ask questions of officers of the Company, which questions were answered to its satisfaction. The Investor believes that it has received all the information that it considers necessary or appropriate
for deciding whether to acquire the Securities. The Investor understands that any such discussions, as well as any information issued by the Company, were intended to describe certain aspects of the Company’s business and prospects, but were
not necessarily a thorough or exhaustive description. The Investor acknowledges that any business plans prepared by the Company have been, and continue to be, subject to change and that any projections included in such business plans or otherwise
are necessarily speculative in nature, and it can be expected that some or all of the assumptions underlying the projections will not materialize or will vary significantly from actual results. 

 6. Accredited Investor. The Investor represents that it is an “accredited
investor” within the meaning of Regulation D under the Securities Act and agrees to submit to the Company further assurances of such status as may be reasonably requested by the Company. 

7. Residency. The residency of the Investor (or, in the case of a partnership or corporation, such entity’s principal place of
business) is correctly set forth on the signature page hereto. 
 8. Restrictions on Resales. The Investor acknowledges that the
Securities must be held indefinitely unless subsequently registered under the Securities Act or an exemption from such registration is available. The Investor is aware of the provisions of Rule 144 promulgated under the Securities Act, which
permit resale of shares purchased in a private placement subject to the satisfaction of certain conditions, which may include, among other things, the availability of certain current public information about the Company; the resale occurring not
less than a specified period after a party has purchased and paid for the security to be sold; the number of shares being sold during any three-month period not exceeding specified limitations; the sale being effected through a “broker’s
transaction,” a transaction directly with a “market maker” or a “riskless principal transaction” (as those terms are defined in the Securities Act or the Securities Exchange Act of 1934, as amended, and the rules and
regulations promulgated thereunder); and the filing of a Form 144 notice, if applicable. The Investor acknowledges and understands that the Company may not be satisfying the current public information requirement of Rule 144 at the time the
Investor wishes to sell the Securities and that, in such event, the Investor may be precluded from selling the Securities under Rule 144 even if the other applicable requirements of Rule 144 have been satisfied. The Investor understands
and acknowledges that, in the event the applicable requirements of Rule 144 are not met, registration under the Securities Act or an exemption from registration will be required for any disposition of the Securities. The Investor understands
that, although Rule 144 is not exclusive, the Securities and Exchange Commission has expressed its opinion that persons proposing to sell restricted securities received in a private offering other than in a registered offering or pursuant to
Rule 144 will have a substantial burden of proof in establishing that an exemption from registration is available for those offers or sales and that those persons and the brokers who participate in the transactions do so at their own risk. 

9. No Public Market. The Investor understands and acknowledges that no public market now exists for any of the securities issued by the
Company and that the Company has made no assurances that a public market will ever exist for the Company’s securities. 
 10. Brokers
and Finders. The Investor has not engaged any brokers, finders or agents in connection with the Securities, and the Company has not incurred nor will incur, directly or indirectly, as a result of any action taken by the Investor, any liability
for brokerage or finders’ fees or agents’ commissions or any similar charges in connection with the Securities. 
 11. Legal
Counsel. The Investor has had the opportunity to review the Warrant, the exhibits and schedules attached thereto and the transactions contemplated by the Warrant with its own legal counsel. The Investor is not relying on any statements or
representations of the Company or its agents for legal advice with respect to this investment or the transactions contemplated by the Warrant. 

12. Tax Advisors. The Investor has reviewed with its own tax advisors the U.S. federal, state and local and non-U.S. tax consequences of
this investment and the transactions contemplated by the Warrant. With respect to such matters, the Investor relies solely on such advisors and not on any statements or representations of the Company or any of its agents, written or oral. The
Investor understands that it (and not the Company) shall be responsible for its own tax liability that may arise as a result of this investment or the transactions contemplated by the Warrant. 

 13. Market Stand-off.  

(a) Agreement to Lock-Up in connection with IPO. The Investor agrees that the Investor shall not sell or otherwise transfer, make
any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale, of any common stock (or other securities) of the Company held by the Investor (other than those
included in the registration) during the one hundred and eighty (180) day period following the effective date of the registration statement for the Company’s initial public offering filed under the Securities Act (or such other period as
may be requested by the Company or an underwriter to accommodate regulatory restrictions on (i) the publication or other distribution of research reports and (ii) analyst recommendations and opinions, including, but not limited to, the
restrictions contained in FINRA NASD Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto). The obligations described in this section shall not apply to a registration relating solely to employee
benefit plans on Form S-l or Form S-8 or similar forms that may be promulgated in the future, or a registration relating solely to a transaction on Form S-4 or similar forms that may be promulgated in the future. The Company may impose stop-transfer
instructions and may stamp each certificate with a legend with respect to the shares of common stock (or other securities) subject to the foregoing restriction until the end of such one hundred and eighty (180) day (or other) period. The
restrictions set forth in this Section 13 shall be applicable to the Investor only if all officers and directors are subject to the same restrictions and the Company uses commercially reasonable efforts to obtain a similar agreement from all
stockholders individually owning more than two percent (2%) of the Company’s outstanding common stock (after giving effect to conversion into common stock of all outstanding preferred stock). The Investor agrees to execute a market
stand-off agreement with the underwriters in the offering in customary form consistent with the provisions of this section. Any discretionary waiver or termination by the Company or the underwriters of the restrictions of any or all of such
agreements with an officer or director of the Company or a stockholder individually holding greater than one percent (1%) of the Company’s outstanding capital stock, calculated on a fully-diluted basis, shall apply pro rata to all holders
subject to such agreements, based on the number of shares subject to such agreements. 
 (b) Agreement to Lock-Up in connection with
Form 10 Registration Statement. Upon the Company’s filing of a Form 10 registration statement, the Investor hereby agrees that it will not, without the prior written consent of the Company, during the period commencing on the date on
which the SEC informs the Company that it has completed its review of the Form 10 registration statement and ending 180 days following the Trading Date, (a) lend, offer, pledge, sell, contract to sell, sell any option or contract to
purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of common stock or (b) enter into any swap or other arrangement that
transfers to another, in whole or in part, any of the economic consequences of ownership of the common stock, whether any such transaction described in clause (a) or (b) above is to be settled by delivery of common stock or other
securities, in cash or otherwise. The foregoing provisions shall not apply to (i) shares of common stock acquired in open market transactions after the Trading Date; (ii) transactions relating to shares of common stock purchased in
accordance with clause (i); (iii) in the case of an Investor that is an entity, a transfer by such Investor to its stockholders, members, partners or other equity holders, provided that no consideration is actually paid for such transfer;
(iv) a repurchase of common stock by the Company at a price no greater than that originally paid by such Investor for such common stock and pursuant to an agreement containing vesting and/or repurchase provisions approved by a majority of the
Company’s board of directors (the “Board of Directors”); (v) in the case of a Investor that is a natural person, a transfer of common stock made for bona fide estate planning purposes, either during
such Investor’s lifetime or on death by will or intestacy to his or her family members or any other person approved by the Board of Directors, or any custodian or trustee of any trust, partnership or limited liability company for the benefit
of, 

 
or the ownership interests of which are owned wholly by, such Investor or any such family members, provided in all cases referred to in this clause (v) that no consideration is actually paid
for such transfer and (vi) the receipt of a stock option, shares of restricted common stock or other awards, or the exercise of a stock option, granted under the Company’s 2008 Equity Incentive Plan, as amended, or other stock option plan
approved by a majority of the Board of Directors. The Investor further agrees to execute such agreements as may be reasonably requested by the Company that are consistent with the provisions of this section or that are necessary to give further
effect thereto. 
 (signature page follows) 

 The Investor is signing this Investment Representation Statement and Market Stand-Off Agreement
on the date first written above. 
  

	
	INVESTOR
	
	  

(Print name of the investor)

	
	  

(Signature)

	
	  

(Name and title of signatory, if applicable)

	
	  

(Street address)

	
	  

(City, state and ZIP)

 EXHIBIT B 

ASSIGNMENT FORM 
  

			
	ASSIGNOR:	  	AS IDENTIFIED ON THE SIGNATURE PAGE HERETO
		
	COMPANY:	  	CONTRAFECT CORPORATION
		
	WARRANT:	  	THE WARRANT TO PURCHASE SHARES OF COMMON STOCK ISSUED ON (THE “WARRANT”)

 DATE:                   
                             
  

	(1)	Assignment. The undersigned registered holder of the Warrant (“Assignor”) assigns and transfers to the assignee named below (“Assignee”) all of the rights of
Assignor under the Warrant, with respect to the number of shares set forth below: 

  

			
	Name of Assignee:	 	  

		
	 Address of Assignee:
	 	  

		
		 	  

		
	 Number of Shares Assigned:
	 	  

 and does irrevocably constitute and appoint
             as attorney to make such transfer on the books of ContraFect Corporation, maintained for the purpose, with full power of substitution in the premises. 

 

	(2)	Obligations of Assignee. Assignee agrees to take and hold the Warrant and any shares of stock to be issued upon exercise of the rights thereunder (and any shares issuable upon conversion thereof) (the
“Securities”) subject to, and to be bound by, the terms and conditions set forth in the Warrant to the same extent as if Assignee were the original holder thereof. 

 

	(3)	Investment Intent. Assignee represents and warrants that the Securities are being acquired for investment for its own account, not as a nominee or agent, and not with a view to, or for resale in connection with,
the distribution thereof, and that Assignee has no present intention of selling, granting any participation in, or otherwise distributing the shares, nor does it have any contract, undertaking, agreement or arrangement for the same, and all
representations and warranties set forth in Section 12 of the Warrant are true and correct as to Assignee as of the date hereof. 

  

	(4)	Investment Representation Statement and Market Stand-Off Agreement. Assignee has executed, and delivers herewith, and is in substantive agreement with all applicable provisions of, an Investment Representation
Statement and Market Stand-Off Agreement in a form substantially similar to the form attached to the Warrant as Exhibit A-1. 

 Assignor and Assignee are signing this Assignment Form on the date first set forth above. 

 

			
	ASSIGNOR	  	ASSIGNEE
		
	  
 (Print name of
Assignor)
	  	  
 (Print name
of Assignee)

		
	  
 (Signature of
Assignor)
	  	  
 (Signature
of Assignee)

		
	  
 (Print name of
signatory, if applicable)
	  	  
 (Print name
of signatory, if applicable)

		
	  
 (Print title of
signatory, if applicable)
	  	  
 (Print title
of signatory, if applicable)

		
	Address:	  	Address:EX-10.1

 Exhibit 10.1 

CHOW EXECUTIVE EMPLOYMENT AGREEMENT 
 This
Executive Employment Agreement (the “Agreement”) is dated July 1, 2014 (the “Effective Date”) between: 
 BIOJECT
MEDICAL TECHNOLOGIES INC. (“BMT”), a corporation incorporated under the laws of the State of Oregon having its principal offices at 7180 SW Sandburg Street, Suite 100, Tigard, OR 97223 and business office at 26212 Dimension Drive,
Suite 260, Lake Forest, CA 92630. 
 BIOJECT INC. (“Bioject,” and together with BMT, the “Company”), a corporation
incorporated under the laws of the State of Oregon having its principal offices at 7180 SW Sandburg Street, Suite 100, Tigard, OR 97223 AND: 

Tony K. Chow, having an office address at 26212 Dimension Drive, Suite 260, Lake Forest, CA 92630. 

(“Executive”). 

RECITALS 

WHEREAS, the Executive has heretofore been employed by the Company. 

WHEREAS, the Company and Executive desire to set forth in this agreement the terms and conditions of
Executive’s employment with the Company. 
 NOW, THEREFORE, in consideration of the
mutual promises and covenants herein contained, the parties agree as follows: 
  

	1.	The Company desires to secure the services and expertise of Executive and to ensure the availability of Executive to the Company; and 

 

	2.	Executive desires to serve in the employ of the Company on a full-time basis for the period and upon the terms and conditions provided for in this Agreement. 

NOW THEREFORE, in consideration of the premises and mutual covenants contained herein, the parties noted above agree as follows: 

Section 1 - Employment, Duties and Term 
  

	1.1	Employment. Effective as of the first date set forth above, the Company agrees to employ Executive in the position of Chief Financial Officer, and Executive hereby accepts such employment, on the terms and
conditions set forth herein. Executive’s first day of employment hereunder shall the Effective Date (the “Initial Employment Date”). 

  

	1.2	Approval by the Board. The Company represents that the appointment of Executive to the position referred to in Section 1.1 has been approved by the Board of Directors of the Company (the “Board”)
and that all corporate action required to effect the appointment has been taken. 

  

	1.3	Duties. The Executive shall devote his full-time and best efforts to the Company and to fulfilling the duties of his position which shall include all duties commonly incident to the offices of Chief Financial
Officer. The Executive hereby accepts and agrees to such engagement of services, and will devote himself to the operation of the Company’s business. The Executive shall comply with the Company’s policies and procedures to the extent they
are not inconsistent with this Agreement, in which case the provisions of this Agreement shall prevail. Executive shall comply with all legal requirements applicable to his position, including without limitation, requirements arising out of the
Sarbanes-Oxley Act of 2002. 

  
 1 

	1.4	Reporting. In conducting Executive’s duties under this Agreement, Executive shall report to the Company’s Board of Directors. 

 

	1.5	Location of Employment. The Executive shall conduct his duties under this Agreement primarily at the offices of the Company in Tigard, Oregon, or such other geographical locations as shall be reasonably required
in order to assure the efficient and proper operation of the Company. 

 Section 2 - Base Compensation and Benefits 

 

	2.1	Base Salary. For all services rendered under this Agreement, the Company shall pay Executive a Base Salary at an annual rate of $90,000. Company shall pay Executive in approximately equal monthly amounts pursuant
to its standard payroll schedule. All amounts paid to Executive under this Agreement shall be reduced by such amounts as are required or permitted to be withheld by law. Executive’s Base Salary shall be subject to periodic adjustment by the
Board. The Board will perform performance reviews with respect to the period ending December 31, 2014 and annually thereafter, provided that the Board shall be under no obligation to increase Executive’s Base Salary in connection with any
such review. For purposes of this Agreement, “Base Salary” shall mean regular salary paid on a periodic basis exclusive of benefits, bonuses, stock options, restricted stock unit awards or incentive payments. 

 

	2.2	Benefits. Subject to eligibility requirements, Executive shall be entitled to receive such insurance and other employment benefits as are available to other executive officers of Company under the same terms and
conditions applicable to such other executive officers, which shall initially consist of medical insurance, dental and vision insurance, participation in the Company’s flexible spending account, short- and long-term disability insurance, life
insurance, supplemental life insurance (via portability provision), supplemental medical expense insurance (AFLAC), participation in the Company’s 401(k) plan and employee stock plan, and other benefits that the Company may offer from time to
time. Such benefits may change from time to time or may be eliminated by Company. 

  

	2.3	Business Expenses. The Company shall, in accordance with, and to the extent of, its policies in effect from time to time, reimburse all ordinary and necessary business expenses reasonably incurred by Executive in
performing his duties as an employee of the Company, provided that Executive accounts promptly for such expenses to the Company in the manner prescribed from time to time by the Company. Examples of such expenses include travel expenses, remote home
office expenses and personal computer and peripherals used for business purposes. 

  

	2.4	Vacation. Executive shall be entitled to vacation, flexible time off, paid holidays and sick leave according to the standard policies and procedures of the Company; provided that Executive shall be entitled to 15
vacation days per year, with the unused vacation in any year to be available for use in subsequent years. 

 Section 3 - Stock
Options; Incentive Compensation 
  

	3.1	Stock Options. Bioject has an executive stock option program. The Chief Financial Officer is eligible for the program, the grants to be determined by Bioject’s Board of Directors Compensation Committee.

  

	3.2	Incentive Compensation. The Executive shall be eligible for incentive compensation on an annual basis as determined by Bioject’s Board of Directors Compensation Committee based on the achievement of
corporate objectives. The first period is January 1, 2015-June 30, 2015. 

 Section 4 - Term, Termination 

 

	4.1	Term. The term of this Agreement shall commence on the date first written above (the “Effective Date”). It shall continue for an initial term of one (1) year, subject to the early termination
provisions set forth in this Section 4. Upon expiration of the initial term, this Agreement will be automatically extended for additional one-year terms unless Executive or the Company shall, upon 120 days written notice to the other, elect not
to extend this Agreement for an additional one-year term. Non-renewal of the Agreement by the Company shall be deemed a termination pursuant to Section 4.3 and shall be subject to the severance benefits related to termination under
Section 4.4. 

  
 2 

	4.2	Termination by the Company for Cause. At any time during the term of this Agreement, the Company may terminate this Agreement and Executive’s employment immediately for “Cause” as that term is
defined herein, upon written notice to Executive. 

  

	 	4.2.1.	“Cause” means any one of the following: (a) a material breach of Executive’s duties hereunder, followed by Executive’s failure to cure such breach within a reasonable period of time after
a written demand for such satisfactory performance which specifically and with reasonable detail identifies the manner in which it is alleged that Executive has not satisfactorily performed such duties, provided, however, that no termination for
Cause pursuant to this subparagraph 4.2.1 will be effective until after Executive, together with Executive’s counsel, have had an opportunity to be heard before the Board; (b) a criminal act (excluding motor vehicle violations) by the
Executive reflecting adversely on the business or reputation of the Company; or (c) Executive, in his personal capacity, is indicted or sanctioned or enters into a consent decree, in connection with any investigation of, allegation of
wrongdoing by, or other formal proceeding against Executive, by the United States Food and Drug Administration or the United States Securities and Exchange Commission, whether related to the business of the Company or to any other past employment or
activity of Executive. 

  

	 	4.2.2.	In the event of Executive’s termination for Cause pursuant to Section 4.2, all forms of compensation and benefits payable to Executive pursuant to Sections 2 and 3 shall terminate on the date of
termination. Executive shall not be entitled to any additional compensation or severance. 

  

	4.3	Termination by the Company Without Cause; Termination by Executive for Good Reason. The Company may terminate this Agreement and Executive’s employment at any time without Cause upon giving Executive at
least 10 days written notice. Executive may terminate this Agreement and his Employment for Good Reason upon giving the Company at least 30 days written notice specifying the reason and failure of the Company to remedy the condition within 30 days.
“Good Reason” means a material reduction in Executive’s title or duties. Termination of employment because of disability under Section 2.5 and termination of employment because of death under 4.1 are not terminations under this
Section 4.3 or Section 4.4. 

  

	4.4	Severance Benefits. If (i) the Company gives notice pursuant to Section 4.1 that the term of this Agreement shall not be extended or shall not be renewed, (ii) this Agreement and Executive’s
employment are terminated by the Company pursuant to Section 4.3, or (iii) Executive terminates his employment for Good Reason pursuant to Section 4.3, then as of the effective date of Executive’s termination: 

 

	 	4.4.1.	The Company shall pay Executive as severance pay an amount equivalent to three month (3) months of Executive’s then-current Base Salary plus accrued and unused vacation (the “Severance Pay”).
The Company may pay such Severance Pay on dates generally coinciding with its regular payroll schedule or in a single lump sum payment in its sole discretion; and 

 

	 	4.4.2.	An amount equivalent to the premium Executive would pay if Executive were to elect to continue Executive’s group health benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985
(“COBRA”) for a period of three (3) months; and 

  

	 	4.4.3.	As a condition of receiving the compensation and other benefits pursuant to this Section 4.4, Executive shall sign, deliver and not revoke a release of claims in a reasonable form to be provided by the
Company at the time of termination. 

  

	4.5	Termination by Executive. The Executive may terminate this Agreement at any time by giving 60 days prior written notice to the Company. Upon termination of this Agreement by Executive pursuant to this
Section 4.5, Executive shall be paid unpaid salary and accrued and unpaid vacation through the date of termination. All other forms of compensation payable to Executive pursuant to Section 2 shall terminate on the date of termination.
Executive shall not be entitled to any additional compensation or severance. 

  
 3 

 Termination Upon Death or Disability. This Agreement shall terminate immediately upon
Executive’s death or disability. In the event of Executive’s death The Company shall pay to Executive’s estate the Base Salary otherwise payable to Executive through the last day of the calendar month in which Executive’s death
occurs. As expeditiously as possible after Executive’s death the Company shall pay or reimburse Executive’s estate for all expenses incurred pursuant to Section 2.3 prior to such death. If Executive becomes disabled (as defined in the
Company’s disability insurance policies) during the term of the Agreement, and Executive’s sole remedy shall be to receive three (3) months of Executive’s then monthly base salary, less the present value of any benefits to be
paid to Executive under the Company’s Short and Long Term Disability Policies (the “Policies”) in effect at that time. 
  

	4.6	Acts Upon Termination. Upon termination of Executive’s employment with the Company, all computers, equipment, documents, records, notebooks, and similar repositories of or containing Confidential
Information, including copies thereof, then in Executive’s possession, whether prepared by Executive or others, will be delivered to the Company within thirty (30) days of such termination. The obligations of Executive in Section 5 of
this Agreement shall survive any termination of Executive. 

  

	4.7	Entire Termination Payment. The compensation provided for in this Section 4 shall constitute Executive’s sole remedy for termination of this Agreement by either party. 

 

	4.8	Resignation. Upon termination of Executive’s employment with Company for any reason, Executive shall offer his resignation as an officer or director of any subsidiary or affiliate of the Company in which
he/she holds such positions. 

 Section 5 - Confidentiality, Invention Ownership Agreement and Noncompetition Agreement

  

	5.1	Executive agrees to execute and deliver and abide by the Confidentiality, Invention Ownership Agreement and Noncompetition Agreement executed by Executive on the date of the Agreement (the “Confidentiality
and Noncompetition Agreement”). Upon the termination of Executive’s employment, Executive shall return all confidential information of any type that that belongs to the Company, or any other related or affiliated entity, or a third party.
Executive acknowledges that Executive’s obligations of confidentiality extend beyond the termination of Executive’s employment as dictated by the Confidentiality and Noncompetition Agreement. Executive acknowledges and agrees that upon
Executive’s termination of employment with the Company for any reason, Executive shall be bound by the provisions set forth in the Confidentiality and Noncompetition Agreement as if those provisions were set forth herein. Executive also
acknowledges that Executive’s obligations of noncompetition and nonsolicitation extend beyond the termination of Executive’s employment for any reason as dictated by the Confidentiality and Noncompetition Agreement. 

Section 6 - General Provisions 
  

	6.1	Notices. All notices, requests and demands given to or made pursuant hereto shall, except as otherwise specified herein, be in writing and shall be deemed to have been duly given to any party when delivered
personally (by courier service or otherwise), when delivered by facsimile and confirmed by return facsimile, or three days after being mailed by first-class mail, postage prepaid and return receipt requested in each case to the applicable address as
set forth at the beginning of this Agreement. Either party may change its address, by notice to the other party given in the manner set forth in this Section. 

  

	6.2	Caption. The various headings or captions in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement. 

 

	6.3	Venue and Jurisdiction/Controlling Law. For any claim or cause of action arising under or relating to this Agreement, the Company and Executive consent to the exclusive jurisdiction of the Oregon Superior Court,
or a federal court serving Portland, Oregon, and waive any objection based on jurisdiction or venue, including forum non conveniens; provided, however, if the Company seeks injunctive relief, it may file such action wherever in
its judgment relief might most effectively be obtained. Oregon law shall apply. 

  
 4 

	6.4	Mediation. In case of any dispute arising under this Agreement which cannot be settled by reasonable discussion, except for Company’s right to seek injunctive relief pursuant to the terms of the
Confidentiality and Noncompetition Agreement attached hereto as Exhibit B, the parties agree that, prior to commencing litigation, they will first engage the services of a professional mediator agreed upon by the parties and attempt in good
faith to resolve the dispute through confidential nonbinding mediation. Each party shall bear one-half of the mediator’s fees and expenses and shall pay all of its own attorneys’ fees and expenses related to the mediation.

  

	6.5	Attorney Fees. If any action at law, in equity or by arbitration is taken to enforce or interpret the terms of this Agreement, the prevailing party shall be entitled to reasonable attorneys’ fees, costs and
necessary disbursements in addition to any other relief to which such party may be entitled, including fees and expenses on appeal. 

  

	6.6	Construction. Wherever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement shall be prohibited
by or invalid under applicable law, such provision shall be ineffective only to the extent of such prohibition or invalidity without invalidating the remainder of such provision or the remaining provisions of this Agreement. 

 

	6.7	Waivers. No failure on the part of either party to exercise, and no delay in exercising, any right or remedy hereunder shall operate as a waiver thereof; nor shall any single or partial exercise of any right or
remedy hereunder preclude any other or further exercise thereof or the exercise of any other right or remedy granted hereby or by any related document or by law. 

  

	6.8	Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the Company and its successors and assigns, and shall be binding upon Executive, his administrators, executors, legatees,
and heirs. In that this Agreement is a personal services contract, it shall not be assigned by Executive. 

  

	6.9	Modification. This Agreement may not be and shall not be modified or amended except by written instrument signed by the parties hereto. 

 

	6.10	Entire Agreement. This Agreement constitutes the entire agreement and understanding between the parties hereto in reference to all the matters herein agreed upon. This Agreement replaces and supersedes all prior
agreements or understandings of the parties hereto with respect to the subject matter hereof. 

 6.12 Indemnification and Insurance.
Executive shall be entitled to indemnification from the Company to the fullest extent permitted under Oregon law. The Company shall maintain Directors and Officers insurance, in such amounts as are customary for a company such as the Company. 

In witness whereof, the parties hereto have caused this Agreement to be duly executed and delivered as of the day and year first above written. 

 

							
	Bioject Medical Technologies Inc.	 		 	Executive
				
	By:	 	 /s/ Mark A. Logomasini
	 		 	 /s/ Tony K. Chow

	 Mark A. Logomasini
	 		 	Tony K. Chow
	 President & CEO
	 		 	
			
	Bioject Inc.	 		 	
				
	By:	 	 /s/ Mark A. Logomasini
	 		 	
	 Mark A. Logomasini
	 		 	
	 President & CEO
	 		 	

  
 5 

 EXHIBIT B 

CONFIDENTIALITY, INVENTION OWNERSHIP AGREEMENT AND
NONCOMPETITION AGREEMENT 
 This Confidentiality, Invention Ownership Agreement and Noncompetition
Agreement (“Agreement”) is entered into between Bioject Medical Technologies Inc., an Oregon corporation, Bioject Inc., an Oregon corporation (the foregoing, collectively, the “Company”), and Tony K. Chow (“Employee”).

 RECITALS 

A. Company is engaged in the following business: In the future Company is likely to expand its business to additional products, services and
markets. 
 B. Employee wishes to hold a sensitive position with access to, and requiring knowledge of, Company’s proprietary and
commercially valuable information, including trade secrets and strategic information. Employee also may have contact with Company’s affiliated companies (“Affiliate”) and with Company’s and its Affiliate’s customers,
suppliers, investors and strategic partners (collectively, “Company Business Partners”). Unauthorized use or disclosure of such information, or interference with Company’s relationships with Company Business Partners could cause
Company or Affiliate irreparable injury. This Agreement is intended to assure that proprietary information and materials of the Company and Affiliate and relationships with Company Business Partners, will be protected both during and after
Employee’s employment. 
 AGREEMENT 

In recognition and consideration of Employee’s employment or continued employment by Company, and receipt of further disclosure of
confidential information of Company or Affiliate, the parties agree as follows: 
 1. CONFIDENTIALITY.

 (a) “Confidential Information” means information that relates to the business of Company or Affiliate or any customer of
Company or Affiliate; was created, discovered or developed by, or otherwise has commercial value to, Company or any Affiliate; was designated by Company or Affiliate as being confidential; or under the circumstances surrounding its disclosure ought
in good faith be treated as confidential. “Confidential Information” includes, without limitation: (i) information relating to the Company or Affiliate and the Company Business Partners; (ii) business practices and strategic
plans of Company or Affiliate; (iii) technical, financial, marketing, sales, personnel, management, operations, information technology, analytical or other technical or business information or trade secrets of Company or Affiliate; and
(iv) information received from third parties, including without limitation Company Business Partners, that Company or any Affiliate is obligated to treat as confidential. Confidential Information will not include information Employee can
establish: (i) entered or subsequently enters the public domain without Employee’s breach of any obligation owed Company or Affiliate (or a Company Business Partner); (ii) became known to Employee before Company or Affiliate (or a
Company Business Partner) disclosed such information to Employee; (iii) became known to Employee from a source other than Company or Affiliate (or a Company Business Partner) other than by the breach of an obligation of confidentiality; or
(iv) is independently developed by Employee; provided, however, that Employee acknowledges and agrees that aggregations and compilations of individual documents or items of information that, analyzed individually, may not constitute
Confidential Information or Materials, may in their aggregated or compiled form qualify as Confidential Information and Materials that are subject to the terms of this Section 1. 

(b) “Confidential Materials” means all tangible or written materials containing Confidential Information, including without
limitation, written or printed documents, email correspondence and attachments, electronic files, and computer disks, whether machine or user readable. 

(c) Employee shall not use any Confidential Information or Materials for any purpose other than to further Company’s or Affiliate’
business interests as requested by Company. Without limiting the foregoing, Employee shall not use the Confidential Information or Materials for the benefit of Employee or any third party. Employee shall not disclose any Confidential Information or
Materials to any third party without having first received the express prior written permission of Company. Employee shall at all times keep the Confidential 

  
 1 

 
Information and Materials confidential and shall take all reasonable security precautions to keep confidential and protect the Confidential Information from unauthorized access and use. Employee
may directly or indirectly reproduce, summarize and distribute Confidential Information and Materials only in pursuance of Company’s business as requested by Company, and only as otherwise provided hereunder. 

(d) Employee’s Section 1 obligations shall remain in effect with respect to particular information for the longest time permitted by
applicable law. If Employee is required by subpoena or otherwise to disclose Confidential Information or Materials, Employee shall give Company notice of the proposed disclosure as soon as practicable after learning of the subpoena or the disclosure
requirement and shall make any such disclosure in a manner so as to maximize the protection of the information from further disclosure. 

2. RETURN OF DOCUMENTS AND PROPERTY. At
termination of employment, or earlier if requested, Employee shall promptly surrender to Company, without retaining copies, all tangible and intangible things which are or contain Confidential Information or Materials. Employee shall also return all
files, correspondence, memoranda, computer software and print-outs, computer disks or CDs, work papers, files, client lists, and other property or things which Company or Affiliate gave to Employee, which Employee created in whole or part within the
scope of Employee’s employment, or to which Employee had access, even if they do not contain Confidential Information or Materials. Also, at the time of termination from Company, regardless of reason, Employee shall in good faith take all acts
necessary and reasonable to assure that Employee’s work is efficiently transitioned to Company. 
 3. RESTRICTIVE
COVENANTS. 
 (a) “Competitor” means any person or entity which engages or is preparing to
engage in the design, development, manufacture, sale or commercial offering (whether or not in conjunction with other services that it performs) of any needle free injection product or service useful for any purpose also served by a needle free
injection product or service which Company then sells, offers or markets, or is then preparing to sell, offer or market. 
 (b) During
employment with Company and continuing for twenty-four (24) months thereafter, Employee shall not, unless Company gives its prior written consent: (i) manage, operate, control, or be employed by any Competitor; (ii) consult with, act
as agent for, or otherwise assist any Competitor to compete or prepare to compete with Company; (iii) own any interest (other than a passive investment interest in a publicly traded company) in any Competitor; (iv) take any action
calculated to divert from Company any opportunity or existing business within the scope of its then business; (v) solicit, hire or otherwise engage any person who had been employed by Company during the last six (6) months before
Employee’s termination, to perform services for Employee or any other person or entity; or (vi) solicit, divert, or in any other manner persuade or attempt to persuade any Company Business Partner to alter or discontinue its relationship
with Company or an Affiliate. Because Company’s business is not limited to any specific areas, the covenants contained in sub-parts (i), (ii) and (iii) of this Section 3(b) cannot be limited to any geographic area. Employee
acknowledges that the covenants in this Section 3 are reasonable in scope, area and duration and are necessary to further Company’s legitimate interests in protecting its Confidential Information, business, good will and, if applicable,
relationships with Company Business Partners. 
 4. COPYRIGHTS. Employee acknowledges and agrees that
any and all copyrightable works prepared by Employee within the scope of Employee’s employment by Company will be works made for hire for purposes of U.S. copyright law, that Company will own all rights under copyright in and to such works, and
that Company will be considered the author of all such works. If and to the extent that any jurisdiction should fail to deem any copyrightable work prepared by Employee within the scope of Employee’s employment by Company to be a work made for
hire that is authored and owned by Company, Employee hereby irrevocably assigns to Company all right, title and interest in and to such work. 

Further, Employee hereby waives in favor of Company the provisions of law known as droit moral (moral rights) or any similar law with respect
to Employee’s copyrightable works, including the right to the integrity of any work. Employee agrees to not institute or authorize any other party to institute any action on the grounds that any works produced by Company constitute an
infringement of any of Employee’s droit moral or are in any way a distortion, mutilation or other modification of the works to the prejudice of Employee’s honor or reputation. 

  
 2 

 5. NEW INVENTIONS. Employee agrees to make
prompt and full disclosure to Company, to hold in trust for the sole benefit of Company, and hereby assigns exclusively to Company all of Employee’s rights, title and interest in and to any and all inventions, discoveries, designs,
developments, concepts, techniques, procedures, products, improvements and trade secrets (collectively “Inventions”) that Employee solely or jointly may conceive, develop, reduce to practice or otherwise produce during Employee’s
employment with Company. Employee waives and quitclaims to Company any and all claims of any nature whatsoever that Employee now has or may have in the future for infringement of any patent application, patent, or other intellectual property right
relating to any Inventions so assigned to Company. Both during and after the termination of Employee’s employment at Company, Employee agrees to execute all documents and take all other actions reasonably requested by Company in order to carry
out and confirm the assignments contemplated by this Agreement at Employee’s cost, including without limitation applications for patents, certificates of authorship, and other instruments appropriate for the protection and enforcement of
intellectual property rights throughout the world. If Employee fails to execute, acknowledge, verify or deliver any such document reasonably requested by Company, Employee hereby irrevocably appoints Company and its authorized officers and agents as
Employee’s agent and attorney-in-fact to act in Employee’s place to execute, acknowledge, verify or deliver any such document (as applicable) on
Employee’s behalf. 
 6. EXCLUDED AND LICENSED
INVENTIONS. Employee has attached as Schedule A a list describing all Inventions that Employee is currently developing and all Inventions belonging to Employee and made by Employee before Employee’s employment
with Company that Employee wishes to confirm Employee’s ownership of under this Agreement. If no such list is attached, Employee represents that there are no such Inventions. As to any Invention in which Employee has an interest at any time
before or during Employee’s employment with Company, Employee agrees that if Employee uses or incorporates such an Invention in any released or unreleased Company product, service, program, process, development or work in progress, or if
Employee permits Company so to use or incorporate such an Invention, Company is hereby granted and shall have an irrevocable, perpetual, royalty-free, worldwide license to exercise any and all rights with respect to such Invention, including without
limitation the right to protect, make, have made, use and sell that Invention without restriction and the right to sublicense those rights to others. This license shall be exclusive, subject only to any preexisting non-exclusive licenses or other
pre-existing rights not subject to Employee’s control. 
 7. REMEDIES. Employee acknowledges that
Company would be greatly injured by, and has no adequate remedy at law for, Employee’s breach of Sections 1, 2, 3, 4, 5 or 6. Employee therefore consents that if such breach occurs or is threatened, Company may, in addition to all other
remedies, enjoin Employee (together with all persons acting in concert with Employee) from such breach or threatened breach. If an injunction is granted, the periods in Sections 1 and 3 shall be extended so as to commence when such injunction is
entered. 
 (A) ATTORNEYS’ FEES. In any claim arising out of or
relating to this Agreement, the substantially prevailing party shall recover its reasonable costs and attorneys’ fees to the extent permitted by law. 

(B) VENUE AND JURISDICTION/CONTROLLING
LAW. For any claim or cause of action arising under or relating to this Agreement, Company and Employee consent to the exclusive jurisdiction of the Washington County, Oregon Superior Court, or a federal court
serving Portland, Oregon, and waive any objection based on jurisdiction or venue, including forum non conveniens; provided, however, if Company seeks injunctive relief, it may file such action wherever in its judgment relief
might most effectively be obtained. Oregon law shall apply, excluding its choice of law rules. 
 8. EMPLOYMENT
AT WILL. Nothing in this Agreement shall affect Employee’s at-will employment relationship. Employee’s employment with Company may be terminated by Company or Employee and for any reason or
no reason, subject to the requirements of the Executive Employment Agreement between Employee and Company. Employee shall comply with all Company policies and procedures, as modified from time to time. Employee shall execute such additional
documents, including agreements, as Company may request to ensure compliance with requirements of Company, Affiliate and Company Business Partners legal and ethical obligations. 

  
 3 

 9. ASSIGNMENT. Company may assign rights and duties under
this Agreement, but Employee may not. This Agreement shall bind Employee’s heirs and personal representatives, and inure to the benefit of Company and its successors and/or assigns. Affiliate are third-party beneficiaries of this Agreement.

 10. FREEDOM TO CONTRACT. Employee warrants that he or
she has the full power and authority to enter into and perform according to the terms of this Agreement and is under no disability or obligation, express or implied, to any other party, including former employers, that prevents him or her from
entering into this Agreement or from complying with all of its provisions to the fullest extent. Employee shall comply fully with all confidentiality obligations owed to all third parties, including all former employers, and shall not disclose to
Company any trade secret or proprietary information of any third party that Employee is obligated not to disclose without the written consent of Company and the third party. 

11. COMPLETE AGREEMENT. This Agreement the entire agreement between the parties on its
subject matters, and supersedes all prior and contemporaneous discussions and understandings. This Agreement also is not intended to supersede any document addressing Employee’s rights or duties regarding compensation, benefits or stock
options. No waiver, modification or termination of any term of this Agreement shall be effective unless in writing and signed by both parties. If any provision as written is deemed unlawful, overbroad or otherwise unenforceable, the parties agree to
follow a construction which will give Company the maximum protection which is reasonable and permissible under the circumstances (including, if necessary, a reduction in the time and/or geographic scope of nondisclosure and/or restrictive
covenants), or if this is not possible, it shall be deemed severed. The failure, delay or forbearance on the part of Company to insist on strict performance of any provision of this Agreement, or to exercise any right or remedy, shall not be
construed as a waiver. The waiver of any right or remedy by Company in one or more instances shall not excuse the strict performance of Employee’s duties and obligations. 

12. LEGAL REPRESENTATION. Employee has had the opportunity to review this Agreement with
an attorney of his or her own choosing, or knowingly and voluntarily waived the right to do so. Employee understood this Agreement, and acknowledges that the restrictions in this Agreement are fair and reasonable. 

13. EFFECTIVE DATE. Although this Agreement is signed on February 15, 2013 it is
intended to be effective as of the date that Employee’s employment with Company began. 
  

							
	Bioject Inc.	 		 	Employee
				
	By:	 	 /s/ Mark A. Logomasini
	 		 	 /s/ Tony K. Chow

	 Mark A. Logomasini

President & CEO
	 		 	Tony K. Chow
			
	Bioject Medical Technologies Inc.	 		 	
				
	By:	 	 /s/ Mark A. Logomasini
	 		 	
	 Mark A. Logomasini
	 		 	
	 President & CEO
	 		 	

  
 4 

 Schedule A – Excluded Inventions 

The following is a list of inventions that Employee developed before employment with Company, Inc.: 

NONE 

  
 1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}]]